To assess the mechanisms ofosteopenia in inflammatory bowel disease (IBD), the serum markers of bone formation (osteocalcin and carboxyterminal propeptide of type I procollagen (PICP)) and bone degradation (carboxyterminal telopeptide of type I collagen (ICTP)), the bone mineral density (BMD) of the lumbar spine and the proximal femur and calcium intake of 150 unselected IBD patients and 73 healthy controls were investigated. The patients had higher ICTP values (3.69 (SD 1-40) ,ug/l) than the healthy controls (3.25 (1.00) ,ug/l, p=0.035), but no differences in serum PICP and osteocalcin between these groups were detected. In the patients, the (Gut 1996; 38: 223-228) 
Abstract
To assess the mechanisms ofosteopenia in inflammatory bowel disease (IBD), the serum markers of bone formation (osteocalcin and carboxyterminal propeptide of type I procollagen (PICP)) and bone degradation (carboxyterminal telopeptide of type I collagen (ICTP)), the bone mineral density (BMD) of the lumbar spine and the proximal femur and calcium intake of 150 unselected IBD patients and 73 healthy controls were investigated. The patients had higher ICTP values (3.69 (SD 1-40) ,ug/l) than the healthy controls (3.25 (1.00) ,ug/l, p=0.035), but no differences in serum PICP and osteocalcin between these groups were detected. In the patients, the ICTP, PICP, and osteocalcin values did not have any significant correlation with BMD, but the patients with ICTP values above 3.6 ,ug/l had significantly lower Z scores than those with lower ICTP. In the controls, however, a positive correlation between serum ICTP and BMD was found. The ulcerative colitis patients with total colitis had higher values of ICTP (3.96 (1.58) ,ug/l) than those with a left sided disease (3.04 (0.86) [Lg/l, p=0.009).
The patients with a history of clinically active disease (n=20) had higher ICTP (4.58 (1P55) pg/l) and osteocalcin (12.56 (5.64) ,ug/l) values than the patients (n= 130) with quiescent disease (ICTP 3 56 (1.33), p=0-002, and osteocalcin 9.76 (3.62), p=0017). Increased serum osteocalcin, PICP, and ICTP concentrations and reduced BMD Z scores were found in a subgroup of Crohn's disease patients with a history of an active disease (n= 11). Raised Reduced bone mineral densities (BMD) have been reported in patients with inflammatory bowel disease (IBD). [1] [2] [3] Osteopenia in IBD patients seems to be associated with high lifetime corticosteroid doses,l 3 but other pathogenetic mechanisms, such as disease activity, a reduced absorption of calcium and vitamin D, and a sex hormone deficiency, may also be involved. The diagnosis of osteopenia is based on BMD measurements, dual energy x ray absorptiometry and computerised tomography being currently the most commonly used methods for measurements of the axial skeleton.
The main organic material of mineralised bone is type I collagen. In the recent years, it has become possible to measure simultaneously serum markers that reflect both the formation and degradation of this collagen type. The carboxyterminal propeptide of type I procollagen (PICP) is derived from type I procollagen, and a good correlation between the bone mineralisation rate and the serum PICP concentration has been reported. 4 19 or over 60 years, disease duration less than three years, IBD confined to the rectum only, and pregnancy. As the serum ICTP concentration increases in renal failure, two patients (one man and one woman) with Crohn's disease and nephritis (and high serum ICTP and PICP concentrations) were excluded from this study. The diagnosis, the extent, and the type of the IBD were determined using uniform clinical'0 and pathological 1 criteria.3 All the histological samples were evaluated by one pathologist (TK). The activity of the inflammation was histologically evaluated according to the criteria described by Rutegard et al12 and the extent of active inflammation was determined. Sixty seven patients had ulcerative colitis, 76 had Crohn's disease, and seven had indeterminate colitis. The mean time since the diagnosis of IBD was 11.5 (6.0) (range 3-32) years. The 150 IBD patients were compared with 73 healthy controls with a similar age and sex distribution. Both the patients and the controls came from the same area around Oulu in northern Finland. The mean age of the male patients was 39.6 (8.5) years and that of male controls was 40.9 (9 1) years (NS Calcium intake Dietary calcium intake was estimated using a semiquantitative food frequency questionnaire comprising 48 food items. The same method has been used in a similar study.'8 The subjects who did not use milk products or other dairy products containing considerable amounts of lactose were classified as having a low lactose diet. To minimise seasonal variation, all the interviews and BMD measurements were performed and blood samples taken in April and May 1993.
Statistical analysis
The data are presented as means (SD). Student's unpaired t test was used when appropriate. When the variances were unequal or the distribution was not normal, the MannWhitney U test was used. A comparison of incidences was performed by using x2 statistics or Fisher's exact test. Pearson's correlation coefficients were calculated for the continuous variables. Two tailed values for significance were used in all the statistical tests, and significance was defined as p<0Q05. The analyses were made with the Statistical Package for Social Sciences (SPSS). The statistical software Confidence Interval Analysis (CIA), version 1.0, was used to calculate the 950/o confidence intervals (CI).
Ethical considerations
The study was approved by the ethical committee of the Oulu University Hospital and informed consent was obtained from all the patients and controls before the investigation.
Results
The patients had higher ICTP values than the healthy controls, but no differences in serum PICP and osteocalcin between these groups were detected (Table I) . No sex related difference in the ICTP values was found, but the PICP values were lower in women than in men both in the patients (men 137 (43) ,ug/l and women 119 (35) ,g/1, p=0-012) and in the controls (men 142 (72) ,ug/l and women 115 (34) ,ug/l, p=0.060). In the IBD patients, serum osteocalcin was higher in men (10-8 (4.0) ,ug/l) than in women (9.5 (4.0) ,ug/l, p=0.004), whereas no corresponding difference was found in the controls. Table II were not significantly different from the other IBD patients.
No differences were detected in the serum ICTP, PICP or osteocalcin concentrations between the patients with ulcerative colitis (n=67) and Crohn's disease (n=76). The patients who, during the course of their disease, had had relapses requiring changes in treatment more often than twice a year or continuously had a clinically active disease (n= 20) had higher ICTP (4-58 (1.55) ,ug/l) and osteocalcin (12.6 (5.6) ,g/l) values than the patients (n= 130) with more quiescent disease (ICTP (1-33) ,g/l, p=0002 and osteocalcin 9-8 (3-6) ,ug/l, p=0017). No significant difference in serum PICP between these two groups was detected, but raised serum osteocalcin, PICP, and ICTP and reduced BMD Z scores were found in Crohn's disease patients with a history of active disease. They also had higher serum PICP than the patients with a history of active ulcerative colitis (Table IV) (3.82 (1.38) ,ig/l, p=0045). The ages of the patients in these two groups were not statistically different (40.9 (8.8) and 39.5 (9.5) years, respectively).
Discussion
In this cross sectional study, unselected adult IBD patients had significantly increased serum ICTP concentrations when compared with healthy controls, whereas no differences were found in markers of bone formation PICP, and osteocalcin. The patients with serum ICTP above 3.6 pug/l had higher BMD in the spine and in the proximal femur than the patients with lower serum ICTP values. As would be expected because of the coupling of the bone remodelling, we found positive correlations with serum ICTP and markers of bone formation, alkaline phosphatase, osteocalcin, and PICP. The (Table III) . Further studies are needed to establish the value of the ICTP test in discriminating the IBD patients with an increased risk for the development of osteoporosis and fractures.
In addition to disease activity, impaired nutritional state, sex hormone deficiency and malabsorption of calcium and vitamin D, and treatment with glucocorticosteroids3 are possible pathogenetic factors in IBD associated osteopenia. In a study by Oikarinen et al,25 systemically given glucocorticoids decreased the concentration of PICP in serum. In our study, the small amount of current corticosteroid users did not have different serum osteocalcin, PICP or ICTP concentrations when compared with other IBD patients and no association was found between the total lifetime corticosteroid dose and these laboratory parameters. It is thus possible that the increased type I collagen degradation in IBD reflects a direct effect of disease activity on bone metabolism.
Increased serum ICTP concentrations are commonly seen in rheumatoid arthritis and associated with the aggressivity of the disease.7 8 Although periarticular and general osteoporosis are features of the disease, ICTP can, in principle, also be derived from type I collagen destruction taking place in soft tissues, which also contain type I collagen having trivalent cross links. This could partly explain our findings on the increased serum ICTP in association with total colitis and histologically active colitis. The ulcerative colitis patients with total colitis also had slightly raised serum PICP concentrations suggesting an increased type I collagen synthesis. In a previous study, we were unable to show any association with BMD or the extent or type of IBD.3 If considerable amounts of ICTP were derived from the soft tissues in all IBD patients, increased PICP values as an indicator of increased synthesis of type I collagen resulting from fibrosis and inflammation would be expected. This was, however, found only in a small subgroup of patients with a disease history of active Crohn's disease (Table IV) . Still, the soft connective tissue involvement in IBD may reduce the value of serum PICP and ICTP as markers of bone matrix metabolism. It is also possible that the mechanisms of osteopenia vary according to the type of the IBD and the disease activity. The soft tissue collagen metabolism could be further investigated in patients with IBD by assessing the metabolism of type III collagen, for example, the aminoterminal propeptide of type III procollagen, a marker of type III collagen synthesis. In addition, further studies on the metabolism of type I collagen to assess possible soft tissue involvement with respect to the disease activity and the type of IBD are required.
We conclude that the patients with IBD have increased serum ICTP and normal concentrations of osteocalcin and PICP, suggesting that an increased rate of bone collagen degradation may be the cause for osteopenia in these patients. In active Crohn's disease all of these markers of bone metabolism are increased. In the patients with ulcerative colitis, the greater extent of the disease and the histological activity are associated with increased serum ICTP. As the IBD patients with serum ICTP above 3.6 ,ug/l had reduced BMD, the ICTP test may be useful in discriminating patients at risk for developing osteopenia.
